Please login to the form below

Not currently logged in
Email:
Password:

osteoporosis

This page shows the latest osteoporosis news and features for those working in and with pharma, biotech and healthcare.

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

It also turned down two previously-rejected medicines – Portola’s factor Xa inhibitor anticoagulant Dexxience (betrixaban) and Radius International’s osteoporosis candidate Eladynos (abaloparatide) – for the second time after a

Latest news

More from news
Approximately 9 fully matching, plus 205 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis.

  • Medical affairs - the time for change is now Medical affairs - the time for change is now

    FLIP aims at supporting the implementation of Fracture Liaison Services (FLS) for secondary fracture prevention in patients suffering from osteoporosis. ... FLS is a coordinated multidisciplinary approach to patient care. To date the FLIP programme has

  • Pharma deals in June 2015 Pharma deals in June 2015

    The device, which has been tested in the clinic for the delivery of parathyroid hormone in osteoporosis patients, can be programmed to release drug at precise times and on a

  • Pharma deals during December 2014 Pharma deals during December 2014

    34 (PTH) delivered using Zosano's microneedle patch system for the treatment of osteoporosis.

  • Investing in the future of R&D Investing in the future of R&D

    One of UCB's brightest prospects is its osteoporosis candidate romosozumab. In January phase II trial results were published that showed significant increases in low bone mineral density at both spine ... and hip and in June the monoclonal antibody began

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • How can pharma engage with key stakeholders on NHS service transformation?

    NHS RightCare provides examples of this with its long-term condition scenarios, such as ‘ Susan’ s Story: Osteoporosis’, where costs are shown to be reduced by a factor of 10 if

  • Atlantis Healthcare

    haemophilia. hepatitis C. incontinence. multiple sclerosis. osteoporosis . rheumatoid arthritis. Additionally, Atlantis has delivered many programmes to support rare diseases, health screening and blood donor management.

  • Atlantis Healthcare

    haemophilia. hepatitis C. incontinence. multiple sclerosis. osteoporosis . rheumatoid arthritis. Additionally, Atlantis has delivered many programmes to support rare diseases, health screening and blood donor management.

  • Maximising ROI from mature brands

    and Evista drug for osteoporosis, underlines the challenges that pharma companies face when patents expire.

  • Patient Compliance – Cracking that Big Nut!

    Non-adherence is a very common problem and a big issue for pharma, especially in chronic disease areas like diabetes, hypertension and osteoporosis.

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics